Company Encyclopedia
View More
name
Kezar Life Sciences
KZR.US
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc.
1.946 T
KZR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kezar Life Sciences | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    KZR
    +0.16%
    LB filings·
    US
    KZR
    +0.16%

    Kezar Life Sciences | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    KZR
    +0.16%
    LB filings·
    US
    KZR
    +0.16%

    Kezar Life Sciences posts narrower Q3 net loss, cuts workforce by 70%

    Kezar Life Sciences reported a narrower Q3 net loss of $11.2 million, down from $20.3 million last year. The company has reduced its workforce by 70% as part of a strategic review and implemented cost-containment measures. R&D expenses fell to $6.9 million, while G&A expenses decreased by $0.9 million. Analysts currently rate the stock as a "hold" with a median 12-month price target of $6.00, slightly below its recent closing price of $6.18.

    Reuters·
    US
    KZR
    +0.16%
    Reuters·
    US
    KZR
    +0.16%

    Kezar Life Sciences Q3 Operating Expenses USD 11.715 Million

    Nov 12 (Reuters) - Kezar Life Sciences Q3 operating income USD -11.715 million. * Q3 net income USD -11.227 million

    Reuters·
    US
    KZR
    +0.16%
    Reuters·
    US
    KZR
    +0.16%

    Kezar Life Sciences Cuts Workforce by 70% in Major Restructuring

    Kezar Life Sciences Inc. has announced a significant restructuring plan that will cut its workforce by approximately 70%, equating to about 31 employees. This decision is part of the company's ongoing evaluation of strategic alternatives. The company anticipates incurring around $6 million in cash expenditures, mainly for severance payments and related costs, with most expenses expected to be recognized in Q4 2025. Actual costs may vary based on future developments regarding the workforce reduction.

    Reuters·
    US
    KZR
    +0.16%
    Reuters·
    US
    KZR
    +0.16%
    © 2025 Longbridge｜Disclaimer